Therefore, these results emphasize the need for future investigation validating the role of PLC-γ1 as potential therapeutic targets for t(8;21) AML and it showed a possibility to use a combination therapy of anti AML1-ETO with anti PLC-γ1 for t(8;21) AML. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.